Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis

被引:12
|
作者
Fakhouri, Walid [1 ]
Lopez-Romero, Pedro [2 ]
Antonelli, Silvia [3 ]
Losi, Serena [4 ]
Rogai, Veronica [4 ]
Buda, Stefano [5 ]
Sangiorgi, Diego [5 ]
Perrone, Valentina [5 ]
Esposti, Luca Degli [5 ]
机构
[1] Eli Lilly & Co, Erl Wood, England
[2] Eli Lilly & Co, Madrid, Spain
[3] Eli Lilly Italy SpA, Rome, Italy
[4] Eli Lilly Italy SpA, Sesto Fiorentino, Italy
[5] CliCon Srl, Hlth Econ & Outcomes Res, Via Salara 36, I-48100 Ravenna, Italy
来源
OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS | 2018年 / 10卷
关键词
rheumatoid arthritis; treatment patterns; drug utilization; real-world data;
D O I
10.2147/OARRR.S164738
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: This study aimed to: 1) describe treatment patterns and drug utilization profile (in terms of therapeutic strategy used, switch, persistence and drug consumption variation) among adult patients affected by rheumatoid arthritis (RA), and 2) estimate the health care resource utilization and its associated direct cost for the management of RA patients. Methods: A retrospective cohort analysis, using administrative databases of six Local Health Units in Italy, was performed. All adult patients with a confirmed diagnosis of RA between January 1, 2010 and December 31, 2014 were enrolled. The date of the first RA diagnosis according to the study criteria during the study period represented the index date (ID) for each patient. Patients enrolled were observed from the ID for at least 12 months (follow-up period), and their clinical characteristics were investigated for 12 months prior to the ID. Results: A total of 10,401 patients with a confirmed RA diagnosis were included. Mean age was 63.0 years and 25% were male; 67% of patients were untreated at ID. During the followup period, 67.8% of patients treated with biologic agents were persistent with initial therapy, compared to 45.7% for patients on conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), while 11% of patients treated with biologic agents switched during the follow-up period, compared to 17.6% of csDMARDs-treated ones. At the end of the follow-up period, 14.7% of all patients in the analysis had an increase and 12.6% of them had a decrease in their initial drug consumption. The mean cost per RA patient was (sic)3,743. Conclusion: Our study showed that there is still much that needs to be learned about the prescription of csDMARDs and biologics to RA patients in Italy and to identify areas for future research. The knowledge of RA management in a real-life clinical setting could offer an opportunity to improve the management of RA in Italy.
引用
收藏
页码:103 / 111
页数:9
相关论文
共 50 条
  • [1] TREATMENT PATTERNS, HEALTH CARE RESOURCE UTILIZATION AND COSTS IN PATIENTS AFFECTED BY SCHIZOPHRENIA IN ITALY: FINDINGS FROM A RETROSPECTIVE ADMINISTRATIVE DATABASE ANALYSIS
    Perrone, V
    Sangiorgi, D.
    Buda, S.
    Degli Esposti, L.
    VALUE IN HEALTH, 2018, 21 : S76 - S76
  • [2] Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis
    Toro, Walter
    Yang, Min
    Georgieva, Mihaela
    Song, Wei
    Patel, Anish
    Jiang, Anya
    Zhao, Angela
    LaMarca, Nicole
    Dabbous, Omar
    ADVANCES IN THERAPY, 2023, 40 (10) : 4589 - 4605
  • [3] Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis
    Walter Toro
    Min Yang
    Mihaela Georgieva
    Wei Song
    Anish Patel
    Anya (Xinyi) Jiang
    Angela Zhao
    Nicole LaMarca
    Omar Dabbous
    Advances in Therapy, 2023, 40 : 4589 - 4605
  • [4] Resource Utilization and Health Care Costs Associated with Diverticulitis: Results from A Retrospective Claims Database Analysis
    Yen, Linnette
    Davis, Keith
    Longstreth, George
    Streck, Paul
    Hodgkins, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S431 - S431
  • [5] Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis
    Vanderpoel, Julie
    Tkacz, Joseph
    Brady, Brenna L.
    Ellis, Lorie
    CLINICAL THERAPEUTICS, 2019, 41 (06) : 1080 - 1089
  • [6] Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims data
    Stirnadel-Farrant, Heide A.
    Xu, Xiao
    Kwiatek, Justin
    Jain, Priya
    Meyers, Juliana
    Candrilli, Sean
    Mines, Daniel
    Datto, Catherine J.
    JAAD INTERNATIONAL, 2023, 13 : 117 - 125
  • [7] TREATMENT PATTERNS AND HEALTHCARE COSTS OF RHEUMATOID ARTHRITIS (RA) PATIENTS IN ITALY
    Perrone, V
    Sangiorgi, D.
    Crovato, E.
    Buda, S.
    Degli Esposti, L.
    VALUE IN HEALTH, 2016, 19 (07) : A536 - A536
  • [8] HEALTH CARE RESOURCE UTILIZATION COSTS RELATED TO ANAEMIA MANAGEMENT IN CHRONIC KIDNEY DISEASE NON-DIALYSED PATIENTS: A RETROSPECTIVE CLINICAL AND ADMINISTRATIVE DATABASE ANALYSIS
    Degli Esposti, L.
    Pelosi, C.
    Saragoni, S.
    Buda, S.
    VALUE IN HEALTH, 2013, 16 (07) : A634 - A634
  • [9] TREATMENT PATTERNS AND COSTS OF CARE IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM THE PERSPECTIVE OF THE HEALTH SERVICE PROVIDER IN MEXICO
    Contreras, I
    Juarez-Garcia, A.
    Martinez-Rivera, G.
    Vallejos Paras, A.
    Ojeda Mendez, J.
    Villasis-Keever, A.
    Rangel, S.
    VALUE IN HEALTH, 2011, 14 (07) : A537 - A537
  • [10] ESTIMATING HEALTH CARE RESOURCE UTILIZATION OF PATIENTS WITH RHEUMATOID ARTHRITIS IN TAIWAN USING A NATIONAL CLAIMS DATABASE
    Tang, C. H.
    Wang, B. C. M.
    Furnback, W. E.
    Ney, J. P.
    Yang, Y. W.
    Fang, C. H.
    Hsu, P. N.
    VALUE IN HEALTH, 2014, 17 (07) : A774 - A774